We scan new podcasts and send you the top 5 insights daily.
Edward van Vaesel says pharma claims to want early assets but usually gets interested only after Phase 2A de-risking. BGV's original plan was proof-of-concept then partner, yet it now has two Phase 3 companies; the partnering bar has moved meaningfully later overall for biotech startups.
Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.
While the CEO of Transgene aspires to launch their product independently in Europe, he acknowledges the immense cost of a Phase 3 trial. A partnership with a large pharmaceutical company is viewed as the most realistic "best case scenario" to accelerate development and de-risk the final, most expensive stage.
The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.
VCs facilitate connections with potential pharma acquirers long before an exit is imminent. Pharma prefers to track a company's progress and data evolution over time. A relationship built gradually by 'following the story' is far more effective than a cold introduction at the final milestone.
Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.
In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.
Despite claims of interest in early-stage innovation, big pharma companies typically wait for significant de-risking before acquiring or partnering. BGV's founder observes that real interest usually materializes only after Phase 2A data, forcing venture-backed biotechs to carry assets further than acquirers' stated appetites suggest.
A profound capital shift has occurred where both venture investors and large pharma partners focus on clinically validated assets. This moves investment away from riskier, early-stage science, creating a significant funding gap for foundational research and pre-clinical startups.
The profile of a company prepared to go public has matured significantly. Unlike the 2020 boom where IND acceptance was a key milestone, today's IPO candidates typically need Phase 2 or even Phase 3 data, raising the quality bar but shrinking the potential pool of companies.
The venture capital landscape for biotech has fundamentally changed. While investors previously funded companies based on preclinical or early-stage clinical results, the new expectation is often Phase 2 proof-of-concept data. This shift significantly increases the early-stage funding and development burden on founders before they can secure major investment.